163 related articles for article (PubMed ID: 7813550)
1. Preclinical pharmacology of FG5893: a potential anxiolytic drug with high affinity for both 5-HT1A and 5-HT2A receptors.
Albinsson A; Björk A; Svartengren J; Klint T; Andersson G
Eur J Pharmacol; 1994 Aug; 261(3):285-94. PubMed ID: 7813550
[TBL] [Abstract][Full Text] [Related]
2. 5-HT1A autoreceptor-mediated effects of the amperozide congeners, FG5865 and FG5893, on rat brain 5-hydroxytryptamine neurochemistry in vivo.
Hjorth S; Pettersson G
Eur J Pharmacol; 1993 Jul; 238(2-3):357-67. PubMed ID: 7691622
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
Kleven MS; Assié MB; Koek W
J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338
[TBL] [Abstract][Full Text] [Related]
4. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
Schreiber R; Brocco M; Audinot V; Gobert A; Veiga S; Millan MJ
J Pharmacol Exp Ther; 1995 Apr; 273(1):101-12. PubMed ID: 7714755
[TBL] [Abstract][Full Text] [Related]
5. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.
Koek W; Patoiseau JF; Assié MB; Cosi C; Kleven MS; Dupont-Passelaigue E; Carilla-Durand E; Palmier C; Valentin JP; John G; Pauwels PJ; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1998 Oct; 287(1):266-83. PubMed ID: 9765347
[TBL] [Abstract][Full Text] [Related]
6. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
Delgado M; Caicoya AG; Greciano V; Benhamú B; López-Rodríguez ML; Fernández-Alfonso MS; Pozo MA; Manzanares J; Fuentes JA
Eur J Pharmacol; 2005 Mar; 511(1):9-19. PubMed ID: 15777774
[TBL] [Abstract][Full Text] [Related]
7. Some pharmacological properties of new analogs of MP 3022, the 5-HT1A receptor antagonist.
Chojnacka-Wójcik E; Kłodzińska A; Tatarczyńska E; Paluchowska MH
Pol J Pharmacol; 1999; 51(5):405-13. PubMed ID: 10817541
[TBL] [Abstract][Full Text] [Related]
8. Interactions of lesopitron (E-4424) with central 5-HT1A receptors: in vitro and in vivo studies in the rat.
Haj-Dahmane S; Jolas T; Laporte AM; Gozlan H; Farré AJ; Hamon M; Lanfumey L
Eur J Pharmacol; 1994 Apr; 255(1-3):185-96. PubMed ID: 8026543
[TBL] [Abstract][Full Text] [Related]
9. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.
Johansson L; Sohn D; Thorberg SO; Jackson DM; Kelder D; Larsson LG; Rényi L; Ross SB; Wallsten C; Eriksson H; Hu PS; Jerning E; Mohell N; Westlind-Danielsson A
J Pharmacol Exp Ther; 1997 Oct; 283(1):216-25. PubMed ID: 9336327
[TBL] [Abstract][Full Text] [Related]
10. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test.
Schreiber R; Melon C; De Vry J
Psychopharmacology (Berl); 1998 Feb; 135(4):383-91. PubMed ID: 9539263
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity.
Foreman MM; Fuller RW; Rasmussen K; Nelson DL; Calligaro DO; Zhang L; Barrett JE; Booher RN; Paget CJ; Flaugh ME
J Pharmacol Exp Ther; 1994 Sep; 270(3):1270-81. PubMed ID: 7523657
[TBL] [Abstract][Full Text] [Related]
12. MP-3022, a new putative antagonist at pre- and postsynaptic 5-HT1A receptors.
Przegaliński E; Filip M; Bijak M; Wedzony K; Budziszewska B; Tokarski K; Maćkowiak M; Fijał K
Pol J Pharmacol; 1996; 48(1):13-22. PubMed ID: 9112623
[TBL] [Abstract][Full Text] [Related]
13. Multiple 5-HT receptors in passive avoidance: comparative studies of p-chloroamphetamine and 8-OH-DPAT.
Misane I; Ogren SO
Neuropsychopharmacology; 2000 Feb; 22(2):168-90. PubMed ID: 10649830
[TBL] [Abstract][Full Text] [Related]
14. Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S 21,357.
Griebel G; Blanchard DC; Rettori MC; Guardiola-Lemaître B; Blanchard RJ
Pharmacol Biochem Behav; 1996 Jun; 54(2):509-16. PubMed ID: 8743616
[TBL] [Abstract][Full Text] [Related]
15. S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors.
Millan MJ; Rivet JM; Canton H; Lejeune F; Bervoets K; Brocco M; Gobert A; Lefebvre de Ladonchamps B; Le Marouille-Girardon S; Verriele L
J Pharmacol Exp Ther; 1992 Aug; 262(2):451-63. PubMed ID: 1323650
[TBL] [Abstract][Full Text] [Related]
16. 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential.
Koek W; Vacher B; Cosi C; Assié MB; Patoiseau JF; Pauwels PJ; Colpaert FC
Eur J Pharmacol; 2001 May; 420(2-3):103-12. PubMed ID: 11408031
[TBL] [Abstract][Full Text] [Related]
17. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635.
Forster EA; Cliffe IA; Bill DJ; Dover GM; Jones D; Reilly Y; Fletcher A
Eur J Pharmacol; 1995 Jul; 281(1):81-8. PubMed ID: 8566121
[TBL] [Abstract][Full Text] [Related]
18. The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes.
Gozlan H; Thibault S; Laporte AM; Lima L; Hamon M
Eur J Pharmacol; 1995 Jan; 288(2):173-86. PubMed ID: 7720779
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
[TBL] [Abstract][Full Text] [Related]
20. 1,4-Benzoxazin-3(4H)-one derivatives and related compounds as 5-HT1A and 5-HT2A receptor ligands; the effect of the terminal amide fragment on the 5-HT1A/5-HT2A affinity and functional activity.
Mokrosz MJ; Kowalski P; Kowalska T; Majka Z; Duszyńska B; Charakchieva-Minol S; Szaro A; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E
Pol J Pharmacol; 1998; 50(4-5):333-40. PubMed ID: 10091718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
